


## **BHARAT BIOTECH – THE COMPANY**

- Founded in 1996 in Genome Valley, Hyderabad, multidimensional product-oriented biotechnology company specializing in R&D, manufacturing, marketing and distribution of vaccines and bio-therapeutics.
- Bharat Biotech's vision has been to generate innovative technologies with a strong backbone of intellectual capital, for manufacturing of unique vaccines with global IPR associated with the products. We have an excellent track record of innovation with 145 active global patents for new technologies for vaccines and therapeutics, staying true to our mission to develop novel technologies to address the health care needs of the developing world.





 Having delivered more than 4 billion doses of vaccines worldwide, we continue to lead innovation and we have a wide product portfolio of more than 16 vaccines, 4 biotherapeutics that includes vaccines for Hepatitis-B, influenza H1N1, Polio, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika and the world's first tetanus-toxoid conjugated vaccine for Typhoid.

PLETHORA OF INNOVATIVE PRODUCTS



\*Data as of December 2020



 Registrations in more than 123 countries along with WHO Pre-qualifications of our products, we significantly impact the global public health.



 The company has proven proficiency in conducting extensive multi-center clinical trials, having completed more than 90 trials enrolling more than ~700,000 participants across continents.





 Our commitment to global social innovation programs and public-private partnerships resulted in the introduction of path-breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC® and Typbar TCV® combating Polio, Rotavirus and Typhoid infections respectively. Bharat Biotech has successfully partnered with NIV-ICMR having developed JENVAC®, a licensed Japanese Encephalitis vaccine.



• The 2019 acquisition of Chiron Behring (CHIRORAB®), has positioned Bharat Biotech as the largest Rabies vaccine manufacturer in the world.